Education
About Us
Working with TipRanks
Follow Us
Zealand Pharma (ZLDPF)
OTHER OTC:ZLDPF
ZLDPF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$61.52 - $141.74
Previous CloseN/A
Volume19.00
Average Volume (3M)809.00
Market Cap
$4.43B
Enterprise Value$42.72B
Total Cash (Recent Filing)kr672.39M
Total Debt (Recent Filing)kr389.18M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
May 08, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding71,051,290
10 Day Avg. Volume488
30 Day Avg. Volume809
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)364.46
Price to Cash Flow (P/CF)-37.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$129.75Price Target Upside109.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Ownership Overview
―
Insiders
18.42% Mutual Funds
― Other Institutional Investors
74.99% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ZLDPF FAQ
What was Zealand Pharma’s price range in the past 12 months?
Zealand Pharma lowest stock price was $61.52 and its highest was $141.74 in the past 12 months.
What is Zealand Pharma’s market cap?
Zealand Pharma’s market cap is $4.43B.
When is Zealand Pharma’s upcoming earnings report date?
Zealand Pharma’s upcoming earnings report date is May 08, 2025 which is in 30 days.
How were Zealand Pharma’s earnings last quarter?
Zealand Pharma released its earnings results on Feb 20, 2025. The company reported -$0.595 earnings per share for the quarter, beating the consensus estimate of -$0.743 by $0.149.
Is Zealand Pharma overvalued?
According to Wall Street analysts Zealand Pharma’s price is currently Undervalued.
Does Zealand Pharma pay dividends?
Zealand Pharma does not currently pay dividends.
What is Zealand Pharma’s EPS estimate?
Zealand Pharma’s EPS estimate is -0.32.
How many shares outstanding does Zealand Pharma have?
Zealand Pharma has 71,051,290 shares outstanding.
What happened to Zealand Pharma’s price movement after its last earnings report?
Zealand Pharma reported an EPS of -$0.595 in its last earnings report, beating expectations of -$0.743. Following the earnings report the stock price went down -1.61%.
Which hedge fund is a major shareholder of Zealand Pharma?
Currently, no hedge funds are holding shares in ZLDPF
---
Company Description
Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
---
ZLDPF Company Deck
---
ZLDPF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, with significant advancements in clinical trials and a strong financial position. However, challenges such as regulatory setbacks and partnership uncertainties were noted.Read More>---
ZLDPF Stock 12 Month Forecast
Average Price Target
$129.75
▲(109.44% Upside)
Technical Analysis
RedHill Biopharma
―
Verastem
―
MannKind
―
Outlook Therapeutics
―
Bristol-Myers Squibb
―
Pfizer
―
Best Analysts Covering ZLDPF
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
+19.72%
reiterated a buy rating 8 months ago
Copying Rajan Sharma's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +19.72% per trade.
---